Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc

Key Points

• Magnolol effectively inhibits AXL and EGFR, leading to reduced tumor growth in resistant lung cancer models.
• The treatment resulted in a significant reduction in cancer cell viability by up to 70% in vitro.
• This analysis included both cellular and molecular assessments to evaluate magnolol's impact on cancer pathways.
• These findings may highlight a potential new strategy for treating resistant forms of lung cancer, but clinical trials are needed.